Year: 2020
APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery
[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]
Abivax announces the success of its oversubscribed capital increase of EUR 28m at market price
[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]
CEVEC and Rznomics sign license agreement for the use of CAP® Technology in manufacturing of adenoviral vectors
[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]
Topas Therapeutics Raises €22 Million (~USD 26 Million) in Series B Financing
[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]
Topas Therapeutics Appoints Klaus Martin, Ph.D. as Chief Executive Officer
[image_slider_no_space on_click=”prettyphoto” height=”600″ navigation_style=”light” images=”940,950,954,952,953,951″]